subscribeSubscribe
KRAZATI with Cetuximab Demonstrates Clinically Meaningful Activity

KRAZATI with Cetuximab Demonstrates Clinically Meaningful Activity
BUSINESSWIRE
08 Apr 2024
Share Share
FDA Accepts sNDA for KRAZATI in Combination with Cetuximab

FDA Accepts sNDA for KRAZATI in Combination with Cetuximab
BUSINESSWIRE
20 Feb 2024
Share Share
Nature Medicine Study Validates Biopsy Assay in Genentech`s Ph 1b of Divarasib

Nature Medicine Study Validates Biopsy Assay in Genentech`s Ph 1b of Divarasib
GLOBENEWSWIRE
11 Dec 2023
Share Share
Lupin launches biosimilar cetuximab in pact with Enzene

Lupin launches biosimilar cetuximab in pact with Enzene
Viswanath Pilla ECONOMICTIMES
30 May 2023
Share Share
Enzene Biosciences launches Cetuximab, biosimilar of cancer drug Erbitux

Enzene Biosciences launches Cetuximab, biosimilar of cancer drug Erbitux
EXPRESSPHARMA
30 May 2023
Share Share
SOLVE FSHD invests in Epic Bio for the deP of a novel treatment

SOLVE FSHD invests in Epic Bio for the deP of a novel treatment
GLOBENEWSWIRE
18 Apr 2023
Share Share
GenFleet receives EMA approval for phase Ib/II study of GFH925 with ERBITUX

GenFleet receives EMA approval for phase Ib/II study of GFH925 with ERBITUX
PR NEWSWIRE
01 Mar 2023
Share Share
GenFleet & Merck Enter into Collaboration to Initiate Study Investigating GFH925

GenFleet & Merck Enter into Collaboration to Initiate Study Investigating GFH925
PRNEWSWIRE
19 Dec 2022
Share Share
Jacobio to Collaborate with Merck on Trial of JAB-21822 with Cetuximab

Jacobio to Collaborate with Merck on Trial of JAB-21822 with Cetuximab
PRNEWSWIRE
12 Oct 2022
Share Share
Jacobio Receives CDE Approval for KRAS G12C Inhibitor JAB-218822`s PII Study

Jacobio Receives CDE Approval for KRAS G12C Inhibitor JAB-218822`s PII Study
PRNEWSWIRE
06 Sep 2022
Share Share